U.S. Biomarker Technologies Market Size, Share & Forecast 2026–2032

ID: MR-11062 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Biomarker Technologies Market
  • ✓Market Size 2024: USD 29.6 billion
  • ✓Market Size 2032: USD 52.5 billion
  • ✓CAGR: 7.5%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Reimbursement Decides Commercial Viability: Medicare's Clinical Laboratory Fee Schedule, reset under PAMA, determines which biomarker assays survive commercially. Guardant Health's Shield blood test secured Medicare coverage through a MolDX technical assessment administered by Palmetto GBA, proving that coverage evidence, not analytical accuracy, sets adoption speed.
FINDING 02
Data Rules Reshape Sequencing: The common view is that the DOJ bulk sensitive data rule under Executive Order 14117 throttles genomic research. In practice, its April 2025 effective date pushes Illumina and Thermo Fisher toward onshore processing, favoring domestic reference laboratories.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Coverage Evidence Early: Diagnostics developers should commission MolDX technical assessment dossiers by Q3 2026, before commercial launch. Pre-submission evidence packages cut Medicare coverage delays that frequently exceed twelve months for novel biomarker tests, securing reimbursement at launch.

Biomarker Technologies in the U.S.: Market Overview

The U.S. biomarker technologies market was valued at USD 29.6 billion in 2024 and is forecast to reach USD 52.5 billion by 2032, growing at a CAGR of 7.5%. The market is structured across genomic sequencing, proteomic assays, imaging biomarkers and liquid biopsy platforms, with reference laboratories and academic medical centers serving as the principal purchasers. Federal research funding through the National Institutes of Health has seeded foundational discovery work, while pharmaceutical sponsors provide the private capital that drives commercial scale.

Policy has shaped this structure more than any single commercial force. The 21st Century Cures Act of 2016 directed the Food and Drug Administration to establish the Biomarker Qualification Program, creating a public pathway for biomarkers used in drug development. Government has been dominant in research funding and evidence standards, while the private sector leads assay commercialization, with Thermo Fisher Scientific, Roche Diagnostics and Illumina capturing most platform revenue.

Policy-Driven Growth in U.S. Biomarker Technologies

The first mechanism is the 21st Century Cures Act (Public Law 114-255), which requires the FDA to accept qualified biomarkers as drug development tools through its formal qualification process. Pharmaceutical sponsors use qualified biomarkers to enrich trial populations, which translates into recurring demand for companion diagnostics and validated assays. Each qualified biomarker converts a one-time research purchase into sustained commercial volume across multi-year clinical trial programs.

The second mechanism is the Precision Medicine Initiative, funded through the Cures Act with USD 4 billion authorized and delivered by the National Institutes of Health as the All of Us Research Program. Its genomic datasets drive sequencing and data-analysis procurement across participating institutions. The third mechanism is the Clinical Laboratory Fee Schedule administered by the Centers for Medicare and Medicaid Services, where reimbursement levels determine whether laboratories adopt new biomarker assays at scale.

Regulatory Barriers and Compliance Costs in U.S. Biomarkers

Clinical Laboratory Improvement Amendments certification, administered by the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendments of 1988, is the first barrier for any laboratory offering biomarker tests. Certification requires proficiency testing, personnel qualifications and quality-control documentation, with application fees and inspection costs running into tens of thousands of dollars per site. Laboratories operating across multiple states must also satisfy state licensing rules, including New York State's Clinical Laboratory Evaluation Program.

The Protecting Access to Medicare Act of 2014 requires CMS to reset Clinical Laboratory Fee Schedule rates using private payer market data collected every three years. Repeated congressional delays to scheduled rate cuts have created pricing uncertainty for test providers. The FDA's laboratory-developed test rule, finalized in 2024, was vacated by a federal court in March 2025, leaving oversight of many biomarker tests fragmented, so developers must budget for both FDA premarket review and CLIA compliance.

Policy-Created Opportunities in U.S. Biomarker Technologies

The Transitional Coverage for Emerging Technologies pathway, finalized by CMS in 2024, creates a Medicare coverage route for breakthrough devices, capped at five technologies annually. Biomarker developers holding FDA Breakthrough Device designation can obtain provisional coverage with evidence development, shortening the revenue lag that has historically deterred early-stage investment. Developers that align trial design with this pathway gain early reimbursement certainty.

The DOJ bulk sensitive data rule, effective April 2025, restricts transfers of U.S. genomic data to countries of concern, creating demand for domestic secure sequencing and data-processing capacity. Laboratories capable of onshore genomic analysis, particularly those contracting with NIH-funded programs, will capture procurement that previously flowed offshore. This shift favors established U.S. reference laboratories and platform vendors with domestic manufacturing footprints.

Market at a Glance

MetricValue
Market Size 2024USD 29.6 billion
Market Size 2032USD 52.5 billion
Growth Rate (CAGR)7.5%
Most Critical Decision FactorMedicare coverage and reimbursement decisions
Largest RegionNortheast (Massachusetts, New York, New Jersey)
Competitive StructureConcentrated in platforms, fragmented in assays

Leading Market Participants

  • Thermo Fisher Scientific
  • Illumina
  • Roche Diagnostics
  • Agilent Technologies
  • Qiagen
  • Guardant Health
  • Natera
  • Exact Sciences
  • Myriad Genetics
  • Danaher

Regulatory and Policy Environment

The primary legislation governing this market is the Federal Food, Drug, and Cosmetic Act, enforced by the Food and Drug Administration for premarket review of companion diagnostics and in vitro diagnostic devices. The Clinical Laboratory Improvement Amendments of 1988 place laboratory-developed tests under CMS oversight, requiring certification, proficiency testing and quality-control documentation. Coverage decisions run through the Medicare Administrative Contractor MolDX program, operated by Palmetto GBA, which evaluates analytical and clinical validity before payment is authorized.

Upcoming changes will shape compliance cost structures. PAMA reporting cycles require private payer rate submissions in 2026 for fee schedule rates effective in 2027, which will recalibrate pricing for multi-gene panels. Compared with regional peers, the U.S. framework lacks the unified premarket certification that the European Union's In Vitro Diagnostic Regulation (EU) 2017/746 imposes through notified bodies, whose transition periods run to 2027 and 2029. This absence leaves U.S. laboratory-developed tests governed mainly by CLIA rather than a device-style premarket standard.

Long-Term Policy Outlook for U.S. Biomarker Technologies

Congress will need to resolve the regulatory status of laboratory-developed tests before 2028, either through legislation modeled on the VALID Act or through a CMS-led evidence framework. Each path will impose different premarket obligations on assay developers, and the choice will determine whether smaller diagnostics firms can sustain multi-biomarker programs. The 2027 PAMA rate cycle will similarly redistribute reimbursement toward validated, clinically useful panels.

By 2032, policy will channel more demand toward domestic genomic infrastructure. Continued enforcement of the DOJ bulk sensitive data rule and expansion of TCET-eligible breakthrough designations will favor U.S.-based sequencing platforms and reference laboratories. Companies that build compliant data governance and coverage evidence into their development programs now will hold the commercial advantage when these frameworks mature.

Frequently Asked Questions

The FDA regulates biomarker devices and companion diagnostics under the Federal Food, Drug, and Cosmetic Act. CMS oversees laboratory quality under the Clinical Laboratory Improvement Amendments of 1988.
The Act created the FDA Biomarker Qualification Program, allowing qualified biomarkers to be used as drug development tools. This creates sustained demand for validated assays across clinical trial programs.
MolDX is a CMS-contracted program operated by Palmetto GBA that evaluates the analytical and clinical validity of molecular diagnostic tests. Its technical assessments determine Medicare coverage and payment for eligible tests.
The rule, issued under Executive Order 14117 and effective April 2025, restricts transfers of bulk U.S. genomic and other sensitive personal data to countries of concern. Compliant operators must maintain onshore processing or approved safeguards.
The EU In Vitro Diagnostic Regulation (EU) 2017/746 requires notified body certification for most diagnostic tests, while U.S. laboratory-developed tests are governed mainly by CLIA. The U.S. framework therefore imposes fewer premarket device obligations but relies more heavily on Medicare coverage evidence.

Market Segmentation

By Technology
  • Next-Generation Sequencing
  • Mass Spectrometry Proteomics
  • Liquid Biopsy
  • Multiplex Immunoassays
  • Digital Pathology Imaging
By Application
  • Companion Diagnostics
  • Drug Development
  • Disease Screening
  • Precision Oncology
By End User
  • Reference Laboratories
  • Hospitals and Health Systems
  • Pharmaceutical and Biotech Companies
  • Academic and Research Institutes

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Biomarker Technologies - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Technology Insights
4.1 Next-Generation Sequencing
4.2 Mass Spectrometry Proteomics
4.3 Liquid Biopsy
4.4 Multiplex Immunoassays
4.5 Others
Chapter 05 Application Insights
5.1 Companion Diagnostics
5.2 Drug Development
5.3 Disease Screening
5.4 Precision Oncology
5.5 Others
Chapter 06 End User Insights
6.1 Reference Laboratories
6.2 Hospitals and Health Systems
6.3 Pharmaceutical and Biotech Companies
6.4 Academic and Research Institutes
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Thermo Fisher Scientific
7.2.2 Illumina
7.2.3 Roche Diagnostics
7.2.4 Agilent Technologies
7.2.5 Qiagen
7.2.6 Guardant Health
7.2.7 Natera
7.2.8 Exact Sciences
7.2.9 Myriad Genetics
7.2.10 Danaher
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.